Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells

Naoko Hida, Nobuhiro Nishiyama, Shunichiro Miyoshi, Shinichiro Kira, Kaoru Segawa, Taro Uyama, Taisuke Mori, Kenji Miyado, Yukinori Ikegami, ChangHao Cui, Tohru Kiyono, Satoru Kyo, Tatsuya Shimizu, Teruo Okano, Michiie Sakamoto, Satoshi Ogawa, Akihiro Umezawa

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Stem cell therapy can help repair damaged heart tissue. Yet many of the suitable cells currently identified for human use are difficult to obtain and involve invasive procedures. In our search for novel stem cells with a higher cardiomyogenic potential than those available from bone marrow, we discovered that potent cardiac precursor-like cells can be harvested from human menstrual blood. This represents a new, noninvasive, and potent source of cardiac stem cell therapeutic material. We demonstrate that menstrual blood-derived mesenchymal cells (MMCs) began beating spontaneously after induction, exhibiting cardiomyocyte-specific action potentials. Cardiac troponin-I-positive cardiomyocytes accounted for 27%-32% of the MMCs in vitro. The MMCs proliferated, on average, 28 generations without affecting cardiomyogenic transdifferentiation ability, and expressed mRNA of GATA-4 before cardiomyogenic induction. Hypothesizing that the majority of cardiomyogenic cells in MMCs originated from detached uterine endometrial glands, we established monoclonal endometrial gland-derived mesenchymal cells (EMCs), 76%-97% of which transdifferentiated into cardiac cells in vitro. Both EMCs and MMCs were positive for CD29, CD105 and negative for CD34, CD45. EMCs engrafted onto a recipient's heart using a novel 3-dimensional EMC cell sheet manipulation transdifferentiated into cardiac tissue layer in vivo. Transplanted MMCs also significantly restored impaired cardiac function, decreasing the myocardial infarction (MI) area in the nude rat model, with tissue of MMC-derived cardiomyocytes observed in the MI area in vivo. Thus, MMCs appear to be a potential novel, easily accessible source of material for cardiac stem cell-based therapy.

Original languageEnglish
Pages (from-to)1695-1704
Number of pages10
JournalStem Cells
Volume26
Issue number7
DOIs
Publication statusPublished - 2008 Jul

Fingerprint

Stem Cells
Cardiac Myocytes
Cell- and Tissue-Based Therapy
Myocardial Infarction
Nude Rats
Troponin I
Action Potentials
Bone Marrow
Messenger RNA
In Vitro Techniques
Therapeutics

Keywords

  • Cardiomyogenesis human mesenchymal stem cell
  • Cell sheet technology cardiac precursors
  • Menstrual blood endometrial gland

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Hida, N., Nishiyama, N., Miyoshi, S., Kira, S., Segawa, K., Uyama, T., ... Umezawa, A. (2008). Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells, 26(7), 1695-1704. https://doi.org/10.1634/stemcells.2007-0826

Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. / Hida, Naoko; Nishiyama, Nobuhiro; Miyoshi, Shunichiro; Kira, Shinichiro; Segawa, Kaoru; Uyama, Taro; Mori, Taisuke; Miyado, Kenji; Ikegami, Yukinori; Cui, ChangHao; Kiyono, Tohru; Kyo, Satoru; Shimizu, Tatsuya; Okano, Teruo; Sakamoto, Michiie; Ogawa, Satoshi; Umezawa, Akihiro.

In: Stem Cells, Vol. 26, No. 7, 07.2008, p. 1695-1704.

Research output: Contribution to journalArticle

Hida, N, Nishiyama, N, Miyoshi, S, Kira, S, Segawa, K, Uyama, T, Mori, T, Miyado, K, Ikegami, Y, Cui, C, Kiyono, T, Kyo, S, Shimizu, T, Okano, T, Sakamoto, M, Ogawa, S & Umezawa, A 2008, 'Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells', Stem Cells, vol. 26, no. 7, pp. 1695-1704. https://doi.org/10.1634/stemcells.2007-0826
Hida N, Nishiyama N, Miyoshi S, Kira S, Segawa K, Uyama T et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells. 2008 Jul;26(7):1695-1704. https://doi.org/10.1634/stemcells.2007-0826
Hida, Naoko ; Nishiyama, Nobuhiro ; Miyoshi, Shunichiro ; Kira, Shinichiro ; Segawa, Kaoru ; Uyama, Taro ; Mori, Taisuke ; Miyado, Kenji ; Ikegami, Yukinori ; Cui, ChangHao ; Kiyono, Tohru ; Kyo, Satoru ; Shimizu, Tatsuya ; Okano, Teruo ; Sakamoto, Michiie ; Ogawa, Satoshi ; Umezawa, Akihiro. / Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. In: Stem Cells. 2008 ; Vol. 26, No. 7. pp. 1695-1704.
@article{8c7a4968af5c4b458a2565c07480f949,
title = "Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells",
abstract = "Stem cell therapy can help repair damaged heart tissue. Yet many of the suitable cells currently identified for human use are difficult to obtain and involve invasive procedures. In our search for novel stem cells with a higher cardiomyogenic potential than those available from bone marrow, we discovered that potent cardiac precursor-like cells can be harvested from human menstrual blood. This represents a new, noninvasive, and potent source of cardiac stem cell therapeutic material. We demonstrate that menstrual blood-derived mesenchymal cells (MMCs) began beating spontaneously after induction, exhibiting cardiomyocyte-specific action potentials. Cardiac troponin-I-positive cardiomyocytes accounted for 27{\%}-32{\%} of the MMCs in vitro. The MMCs proliferated, on average, 28 generations without affecting cardiomyogenic transdifferentiation ability, and expressed mRNA of GATA-4 before cardiomyogenic induction. Hypothesizing that the majority of cardiomyogenic cells in MMCs originated from detached uterine endometrial glands, we established monoclonal endometrial gland-derived mesenchymal cells (EMCs), 76{\%}-97{\%} of which transdifferentiated into cardiac cells in vitro. Both EMCs and MMCs were positive for CD29, CD105 and negative for CD34, CD45. EMCs engrafted onto a recipient's heart using a novel 3-dimensional EMC cell sheet manipulation transdifferentiated into cardiac tissue layer in vivo. Transplanted MMCs also significantly restored impaired cardiac function, decreasing the myocardial infarction (MI) area in the nude rat model, with tissue of MMC-derived cardiomyocytes observed in the MI area in vivo. Thus, MMCs appear to be a potential novel, easily accessible source of material for cardiac stem cell-based therapy.",
keywords = "Cardiomyogenesis human mesenchymal stem cell, Cell sheet technology cardiac precursors, Menstrual blood endometrial gland",
author = "Naoko Hida and Nobuhiro Nishiyama and Shunichiro Miyoshi and Shinichiro Kira and Kaoru Segawa and Taro Uyama and Taisuke Mori and Kenji Miyado and Yukinori Ikegami and ChangHao Cui and Tohru Kiyono and Satoru Kyo and Tatsuya Shimizu and Teruo Okano and Michiie Sakamoto and Satoshi Ogawa and Akihiro Umezawa",
year = "2008",
month = "7",
doi = "10.1634/stemcells.2007-0826",
language = "English",
volume = "26",
pages = "1695--1704",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells

AU - Hida, Naoko

AU - Nishiyama, Nobuhiro

AU - Miyoshi, Shunichiro

AU - Kira, Shinichiro

AU - Segawa, Kaoru

AU - Uyama, Taro

AU - Mori, Taisuke

AU - Miyado, Kenji

AU - Ikegami, Yukinori

AU - Cui, ChangHao

AU - Kiyono, Tohru

AU - Kyo, Satoru

AU - Shimizu, Tatsuya

AU - Okano, Teruo

AU - Sakamoto, Michiie

AU - Ogawa, Satoshi

AU - Umezawa, Akihiro

PY - 2008/7

Y1 - 2008/7

N2 - Stem cell therapy can help repair damaged heart tissue. Yet many of the suitable cells currently identified for human use are difficult to obtain and involve invasive procedures. In our search for novel stem cells with a higher cardiomyogenic potential than those available from bone marrow, we discovered that potent cardiac precursor-like cells can be harvested from human menstrual blood. This represents a new, noninvasive, and potent source of cardiac stem cell therapeutic material. We demonstrate that menstrual blood-derived mesenchymal cells (MMCs) began beating spontaneously after induction, exhibiting cardiomyocyte-specific action potentials. Cardiac troponin-I-positive cardiomyocytes accounted for 27%-32% of the MMCs in vitro. The MMCs proliferated, on average, 28 generations without affecting cardiomyogenic transdifferentiation ability, and expressed mRNA of GATA-4 before cardiomyogenic induction. Hypothesizing that the majority of cardiomyogenic cells in MMCs originated from detached uterine endometrial glands, we established monoclonal endometrial gland-derived mesenchymal cells (EMCs), 76%-97% of which transdifferentiated into cardiac cells in vitro. Both EMCs and MMCs were positive for CD29, CD105 and negative for CD34, CD45. EMCs engrafted onto a recipient's heart using a novel 3-dimensional EMC cell sheet manipulation transdifferentiated into cardiac tissue layer in vivo. Transplanted MMCs also significantly restored impaired cardiac function, decreasing the myocardial infarction (MI) area in the nude rat model, with tissue of MMC-derived cardiomyocytes observed in the MI area in vivo. Thus, MMCs appear to be a potential novel, easily accessible source of material for cardiac stem cell-based therapy.

AB - Stem cell therapy can help repair damaged heart tissue. Yet many of the suitable cells currently identified for human use are difficult to obtain and involve invasive procedures. In our search for novel stem cells with a higher cardiomyogenic potential than those available from bone marrow, we discovered that potent cardiac precursor-like cells can be harvested from human menstrual blood. This represents a new, noninvasive, and potent source of cardiac stem cell therapeutic material. We demonstrate that menstrual blood-derived mesenchymal cells (MMCs) began beating spontaneously after induction, exhibiting cardiomyocyte-specific action potentials. Cardiac troponin-I-positive cardiomyocytes accounted for 27%-32% of the MMCs in vitro. The MMCs proliferated, on average, 28 generations without affecting cardiomyogenic transdifferentiation ability, and expressed mRNA of GATA-4 before cardiomyogenic induction. Hypothesizing that the majority of cardiomyogenic cells in MMCs originated from detached uterine endometrial glands, we established monoclonal endometrial gland-derived mesenchymal cells (EMCs), 76%-97% of which transdifferentiated into cardiac cells in vitro. Both EMCs and MMCs were positive for CD29, CD105 and negative for CD34, CD45. EMCs engrafted onto a recipient's heart using a novel 3-dimensional EMC cell sheet manipulation transdifferentiated into cardiac tissue layer in vivo. Transplanted MMCs also significantly restored impaired cardiac function, decreasing the myocardial infarction (MI) area in the nude rat model, with tissue of MMC-derived cardiomyocytes observed in the MI area in vivo. Thus, MMCs appear to be a potential novel, easily accessible source of material for cardiac stem cell-based therapy.

KW - Cardiomyogenesis human mesenchymal stem cell

KW - Cell sheet technology cardiac precursors

KW - Menstrual blood endometrial gland

UR - http://www.scopus.com/inward/record.url?scp=51649122151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649122151&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2007-0826

DO - 10.1634/stemcells.2007-0826

M3 - Article

C2 - 18420831

AN - SCOPUS:51649122151

VL - 26

SP - 1695

EP - 1704

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 7

ER -